PISCATAWAY,  N.J. – Camber Pharmaceuticals announces the addition of oxcarbazepine tablets to their current portfolio.

Oxcarbazepine tablets are indicated in use as monotherapy or adjunctive therapy in the treatment of partial-onset seizures in adults and as monotherapy in the treatment of partial-onset seizures in pediatric patients aged 4 years and above, and as adjunctive therapy in pediatric patients aged 2 years and above with partial-onset seizures.

Oxcarbazepine tablets from Camber are available in 150, 300, and 600 mg strengths, all in 100 count bottles.

To find out more about oxcarbazepine tablets, visit  https://www.camberpharma.com or see their launch video at https://www.camberpharma.com/oxcarbazepine/